BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12384538)

  • 21. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
    Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
    Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
    Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN
    Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
    Song X; Lin HP; Johnson AJ; Tseng PH; Yang YT; Kulp SK; Chen CS
    J Natl Cancer Inst; 2002 Apr; 94(8):585-91. PubMed ID: 11959891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
    Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
    Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
    Yoshino T; Kimoto A; Kobayashi S; Noguchi M; Fukunaga M; Hayashi A; Miyata K; Sasamata M
    Arzneimittelforschung; 2005; 55(7):394-402. PubMed ID: 16080279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
    Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
    Ninomiya I; Nagai N; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T
    Oncol Rep; 2012 Sep; 28(3):777-84. PubMed ID: 22751903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
    Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
    Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
    Cui W; Yu CH; Hu KQ
    Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
    Reddy BS; Patlolla JM; Simi B; Wang SH; Rao CV
    Cancer Res; 2005 Sep; 65(17):8022-7. PubMed ID: 16140976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
    Kusunoki N; Yamazaki R; Kawai S
    Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
    Abou-Issa HM; Alshafie GA; Seibert K; Koki AT; Masferrer JL; Harris RE
    Anticancer Res; 2001; 21(5):3425-32. PubMed ID: 11848504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
    Lin E; Morris JS; Ayers GD
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):31-7. PubMed ID: 12520638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
    Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K
    Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer.
    Zhang DQ; Guo Q; Zhu JH; Chen WC
    World J Surg Oncol; 2013 Jan; 11():16. PubMed ID: 23347845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
    Zhao S; Cai J; Bian H; Gui L; Zhao F
    Cancer Invest; 2009 Jul; 27(6):636-40. PubMed ID: 19387877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling.
    Yang HM; Kim HS; Park KW; You HJ; Jeon SI; Youn SW; Kim SH; Oh BH; Lee MM; Park YB; Walsh K
    Circulation; 2004 Jul; 110(3):301-8. PubMed ID: 15238462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.